{"id":"W2262509800","doi":"10.1200/jco.2007.25.18_suppl.5093","title":"Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Renal cell carcinoma; Progressive disease; Clinical endpoint; Phases of clinical research; Internal medicine; Adverse effect; Gastroenterology; Performance status; Toxicity; Response Evaluation Criteria in Solid Tumors; Surgery; Urology; Cancer; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001502568,0.001233206,0.001507898,0.0003937713,0.0003406046,0.0006245509,0.0007669225,0.001019767,0.003029989],"category_scores_gemma":[0.0004831923,0.0003989502,0.0005901961,0.0003469578,0.0005955728,0.0003842054,0.0003242203,0.002523105,0.0007641143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008164828,"about_ca_system_score_gemma":0.001360376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008798917,"about_ca_topic_score_gemma":0.001788809,"domain_scores_codex":[0.9996201,0.000182374,0.00001390416,0.00004998846,0.00004741748,0.0000862184],"domain_scores_gemma":[0.9995516,0.00006454579,0.00008950458,0.00003521434,0.00002919847,0.0002299401],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5534739,0.1129566,0.0141195,0.001083718,0.001004531,0.0007812001,0.0003835063,0.004360396,0.1155616,0.000471971,0.008942221,0.1868609],"study_design_scores_gemma":[0.54965,0.4207249,0.01575317,0.00002885264,0.0002845263,0.0006518448,0.00003924845,0.001531252,0.007982158,0.0001381194,0.003190733,0.00002517983],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927811,0.001908948,0.0004319976,0.000410375,0.00006758553,0.002426009,0.0007596001,0.00006881149,0.001145466],"genre_scores_gemma":[0.9859564,0.001908892,0.001927034,0.00075857,0.0002120543,0.002743206,0.002849821,0.00002508303,0.003618964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003029989,"threshold_uncertainty_score":0.01013637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1032877200520177,"score_gpt":0.4469313847711857,"score_spread":0.343643664719168,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}